GlassScriptPhysician profile
Rajalla Prewitt
NPI 1770644064
$1,958.73
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $202 · 2022: $137 · 2023: $815 · 2024: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,129.63 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $409.55 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $283.65 | 2019-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $276.40 | 2020-2024 | Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $216.79 | 2019-2023 | Ingrezza |
| Alkermes, INC. | $200.57 | 2019-2023 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $179.41 | 2019-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Abbvie INC. | $109.12 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $89.35 | 2022 | |
| Sunovion Pharmaceuticals INC. | $51.12 | 2019 | |
| Indivior INC. | $41.01 | 2023-2024 | Sublocade |
| Ironshore Pharmaceuticals INC. | $29.95 | 2019-2020 | |
| Allergan, INC. | $24.27 | 2020 | |
| Vanda Pharmaceuticals INC. | $18.51 | 2019 | |
| Avanir Pharmaceuticals, INC. | $16.51 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajalla Prewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.